Top Institutions in Oncology - Ovarian Cancer and Pharmacology
Leading institutions utilize advanced multimodal imaging techniques including mass spectrometry imaging, spatial transcriptomics, and immunohistochemistry to study drug distribution and tumor heterogeneity in ovarian cancer, integrating molecular profiling with pharmacodynamics to understand resistance.
-
#1
Dana-Farber Cancer Institute
Boston, MA
Dana-Farber is a leader in ovarian cancer research and precision oncology, with extensive expertise in PARP inhibitor clinical trials and advanced imaging techniques to study tumor heterogeneity and drug resistance.
Key Differentiators
- Ovarian Cancer
- Pharmacology
- Mass Spectrometry Imaging
- Molecular Oncology
-
#2
Memorial Sloan Kettering Cancer Center
New York, NY
MSKCC has a robust gynecologic oncology program with cutting-edge research in tumor microenvironment and drug distribution, employing multimodal imaging and molecular profiling to understand PARP inhibitor resistance.
Key Differentiators
- Gynecologic Oncology
- Pharmacodynamics
- Spatial Biology
-
#3
MD Anderson Cancer Center
Houston, TX
MD Anderson combines expertise in cancer pharmacology and molecular imaging to investigate drug distribution and resistance mechanisms in ovarian cancer, with strong programs in lysosomal biology and tumor heterogeneity.
Key Differentiators
- Cancer Pharmacology
- Ovarian Cancer
- Molecular Imaging
-
#4
University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
San Francisco, CA
UCSF is recognized for integrating spatial biology with pharmacological studies in ovarian cancer, advancing understanding of tumor microenvironment influences on drug efficacy and resistance.
Key Differentiators
- Gynecologic Oncology
- Spatial Transcriptomics
- Pharmacology
-
#5
Broad Institute of MIT and Harvard
Cambridge, MA
The Broad Institute excels in integrating genomics and spatial biology technologies to dissect tumor heterogeneity and drug response mechanisms, contributing to understanding PARP inhibitor distribution and resistance.
Key Differentiators
- Cancer Genomics
- Spatial Biology
- Pharmacology
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Newsletters
Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.
